Improvements seen in resilience, stress, anxiety, and burnout-exhaustion after the six-week program
One in 13 U.S. Adults Report Long COVID Symptoms
Rates higher among younger adults and women, with some geographic variation
Immunocompromised Hospitalized With COVID-19 Have Poor Outcomes
Immunocompromised patients have increased odds of ICU admission, in-hospital death, regardless of vaccination status
Can COVID-19 Brain-Fog Be Prevented
A new clinical study recently conducted by the National Institutes of Health (NIH) describes the immune response triggered by COVID-19 infection that damages the brain’s blood vessels and may lead to short- and long-term neurological symptoms.
Published in the peer-review journal Brain on July 5, 2022, researchers examined brain changes in nine people who died suddenly after contracting the SARS-CoV-2 coronavirus.
COVID-19 Vaccination Greatly Reduced Morbidity, Mortality Burden in U.S.
Vaccination estimated to have prevented 52, 56, and 58 percent of expected infections, hospitalizations, deaths in adults from Sept. 1 to 30, 2021
Severe COVID-19 Rates Low With Monoclonal Antibody Therapy During Delta Surge
Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies
Maternal Mortality Up by One-Third During the Pandemic
Increases were highest for Hispanic and non-Hispanic Black women
Prevalence of COVID-19-Related Croup Up During Omicron
Odds of hospitalization not significantly different during periods with alpha or other variant predominance, delta predominance, versus omicron-predominant periods
Israel’s Children Polio Vaccination Campaign Scores a Win
When Israel’s Ministry of Health launched an urgent polio vaccination campaign in March 2022, most parents were unaware of the risks and benefits for their children.
However, as the Health Ministry prepares to end this polio vaccination offering, new data indicates it has been successful among most infants and young children.
Israel Hayom reported on June 27, 2022, that 96% of infants were vaccinated compared to 81% before the campaign.
And the vaccination rate among toddlers aged 18 months to nine years old increased from 69% to 73%.
Will the FDA Ever Authorize a Protein-Based COVID-19 Vaccine?
When the U.S. FDA’s vaccine committee endorsed the Maryland-produced protein-based COVID-19 vaccine on June 7, 2022, many people expected authorization would immediately follow.
However, according to Novavax Inc.’s statement issued on July 1, 2022, this World Health Organization Listed vaccine remains under FDA review.
Novavax stated ‘it is awaiting U.S. emergency use authorization (EUA) for our prototype COVID-19 vaccine, and we are committed to bringing it to market.